Squarepoint’s Keros Therapeutics KROS Stock Holding History

Squarepoint’s Portfolio KROS Stock Details KROS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-31,204	Closed	-$334K	–	4769
2026 Q2	$334K	Buy	+31,204	New	+$348K	﹤0.01%	3726
2025 Q4	–	Sell	-100,141	Closed	-$1.58M	–	4592
2025 Q3	$1.58M	Buy	+100,141	New	+$1.48M	﹤0.01%	2290
2025 Q2	–	Sell	-43,984	Closed	-$448K	–	4783
2025 Q1	$448K	Buy	+43,984	New	+$511K	﹤0.01%	3407
2024 Q4	–	Sell	-4,525	Closed	-$263K	–	5288
2024 Q3	$263K	Sell	4,525 -15,307	-77%	-$756K	﹤0.01%	3539
2024 Q2	$906K	Buy	+19,832	New	+$1.07M	﹤0.01%	2634
2022 Q4	–	Sell	-19,919	Closed	-$749K	–	3423
2022 Q3	$749K	Buy	19,919 +2,204	+12%	+$76.4K	﹤0.01%	1957
2022 Q2	$489K	Buy	+17,715	New	+$777K	﹤0.01%	2026
2021 Q1	–	Sell	-9,035	Closed	-$637K	–	3373
2020 Q4	$637K	Buy	+9,035	New	+$569K	﹤0.01%	1626

Other funds holding KROS

Mackenzie Financial Toronto Ontario, Ontario, Canada $91.6B AUM 30% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $71.4B AUM 33.43% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

O'Shaughnessy Asset Management Stamford, Connecticut $23.6B AUM 34.05% 1-Year Est. Return

Jane Street New York $1.19T AUM 51.51% 1-Year Est. Return

Squarepoint's KROS Position: Q3 2026 in Review

Squarepoint sold out of Keros Therapeutics (KROS) in Q3 2026, closing a stake of 31,204 shares — an estimated $334K sold.

Squarepoint first reported a position in KROS in Q4 2020 and held it in 8 quarters. The position peaked at $1.58M in Q3 2025. 74 funds tracked by Wall St. Rank hold KROS as of Q3 2026.

Squarepoint reported no remaining Keros Therapeutics position as of Q3 2026 after selling out during the quarter.
Squarepoint sold 31,204 Keros Therapeutics shares in Q3 2026, an estimated $334K.
Squarepoint first reported a position in Keros Therapeutics in Q4 2020 and held it in 8 quarters.
Squarepoint's Keros Therapeutics position peaked at $1.58M in Q3 2025.
74 funds tracked by Wall St. Rank held Keros Therapeutics as of Q3 2026.

Based on Squarepoint's 13F filing for Q3 2026, filed 9 Nov 2026.